FDA to Recognize GMP Inspections From Eight EU Countries

Drug GMP Report
A A
The FDA will begin to recognize manufacturing facility inspections conducted by drug regulatory authorities in Austria, Croatia, France, Italy, Malta, Spain, Sweden and the U.K as capable of meeting the agency’s requirements, as part of 1998 agreement between the U.S. and the European Union renegotiated earlier this year.

To View This Article:

Login

Subscribe To Drug GMP Report